QUOTE AND NEWS
TheStreet.com  Oct 31  Comment 
BOSTON (TheStreet) --aWelcome back to this week's Biotech Stock Mailbag. @adamfeuerstein any thoughts on rna after the debacle with srpt? — Joe Smith (@zwerp2000) October 27, 2014 I'm assuming Prosensa completes the submission of...
StreetInsider.com  Oct 30  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Hemispherx+Biopharma+%28HEB%29+Reports+Evidence+Based+Potential+of+Ampligen+Against+Ebola+/9957255.html for the full story.
Benzinga  Oct 22  Comment 
This was a recent headline from earlier this week: "Hemispherx Announces Strategic Relationship with Squire Patton Boggs, Washington, DC as Governmental Counsel in Fight Against Ebola" While a lot of attention has been paid to names such as...
StreetInsider.com  Oct 21  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Hemispherx+Biopharma+%28HEB%29+to+Lobby+For+Additional+Pathways+For+Testing+Ampligen/9926067.html for the full story.
Benzinga  Oct 20  Comment 
Hemispherx Biopharma, Inc. (NYSE MKT: HEB) (the "Company" or "Hemispherx"), has retained Squire Patton Boggs (SPB) to serve as its global government relations team in an effort to help find additional pathways for testing Hemispherx's flagship...
StreetInsider.com  Oct 20  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Hemispherx+Biopharma+%28HEB%29+Reports+Dismissal+of+Claims+in+Cato+Capital+Suit/9922683.html for the full story.
Benzinga  Oct 8  Comment 
The Texas Health Presbyterian Hospital issued a press release Wednesday announcing that the Ebola patient Eric Duncan has died. It appears this is the first case of an Ebola death in the United States. Shares of Ebola-related stocks have...
StreetInsider.com  Oct 1  Comment 
Fannie Mae (OTC: FNMA) 62% LOWER; investors suit against U.S. thrown out Freddie Mac (OTC: FMCC) 61% LOWER; investors suit against U.S. thrown out Tekmira Pharmaceuticals (NASDAQ: TKMR) 21.5% HIGHER; CDC confirms first Ebola case...





You may also be interested in articles related to Hemispherx BioPharma (HEB):

 
TOP CONTRIBUTORS
Hemispherx Biopharma, Inc (HEB) is a medical research company focusing on a new group of medicinal products knows as nucleic acid compounds.

HEB’s main focus is the treatment of Influenza and various Flu Strains through Ampligen®. However, Ampligen® may also serve as a treatment for Chronic Fatigue Syndrome (CFS). Ampligen®, the company’s main candidate is expected to receive FDA approval in the coming weeks. Other projects include Alferon N® which works as an indicator for recurring herpes.

Lack of diversified products, alternative remedies, failure to be approved by the FDA, and possible lawsuits from patients after approval, make this a very high risk company. But if approval by the FDA and wide acceptance of doctors world wide is accomplished many investors expect the stock value to rise too significantly too pass this investment by.

It is a New York City based corporation trading on AMEX.



References

http://www.google.com/finance?q=heb , http://www.hemispherx.net , http://www.pr-inside.com/post-approval-hemispherx-ampligen-pps-r1293461.htm ,

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki